Corbus Pharmaceuticals Holdings ( (CRBP) ) has released its Q3 earnings. Here is a breakdown of the information Corbus Pharmaceuticals Holdings presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity treatments, leveraging innovative scientific approaches to target well-understood biological pathways. Based in Norwood, Massachusetts, Corbus is advancing a pipeline that includes CRB-701, an antibody drug conjugate targeting Nectin-4 in cancer cells, CRB-601, an anti-integrin monoclonal antibody for solid tumors, and CRB-913, a CB1 receptor inverse agonist for obesity treatment.
In its third-quarter 2025 financial results, Corbus Pharmaceuticals reported significant progress in its clinical programs and financial health. The company presented promising data for its CRB-701 drug candidate at the ESMO 2025, showing notable objective response rates in various cancers. Additionally, Corbus successfully completed a $75 million public offering, extending its financial runway into 2028.
Key highlights from the report include the robust clinical data for CRB-701, with objective response rates of 47.6% in head and neck squamous cell carcinoma (HNSCC), 37.5% in cervical cancer, and 55.6% in metastatic urothelial carcinoma (mUC). The company plans to initiate a registrational study for CRB-701 in mid-2026. Furthermore, Corbus is advancing its CRB-913 program, with plans to complete a single and multiple ascending dose study and start a Phase 1b trial in obese patients by the end of 2025.
Financially, Corbus reported a net loss of $23.3 million for the third quarter of 2025, up from $13.8 million in the same period of 2024, primarily due to increased clinical development expenses. However, the company’s cash position remains strong, with $104 million in cash, cash equivalents, and investments as of September 30, 2025, bolstered by recent fundraising activities.
Looking ahead, Corbus Pharmaceuticals is poised to continue its clinical advancements and maintain a strong financial position. The company is optimistic about its ongoing discussions with the FDA and the potential for its innovative drug candidates to address unmet needs in oncology and obesity treatment.